Skip to main content
Premium Trial:

Request an Annual Quote

Incyte Completes Synteni Acquisition, Begins to Integrate Product Lines

Premium

PALO ALTO, Calif.--Incyte Pharmaceuticals has completed its acquisition of the gene expression microarray company Synteni that was announced in December. The transaction involves Incyte's issuing shares of its common stock in exchange for all of Synteni's outstanding equity.

"The integration of Synteni's proven microarray technology and Incyte's genomic information is well underway," commented Randy Scott, Incyte's president and chief scientific officer. "We have already identified and initiated development of a series of new microarray products for launch beginning this year, including two microarrays with applications in pharmacology and toxicology and a panel of microarrays comprising Incyte's entire set of human genes. Combined with Incyte's efforts to identify every human gene, this program should enable us to provide our pharmaceutical partners with the ability to scan virtually every gene in the human genome across any biological sample by the year 2000."

Filed under

The Scan

Two J&J Doses

Johnson & Johnson says two doses of its SARS-CoV-2 vaccine provides increased protection against symptomatic COVID-19, CNN reports.

Pfizer-BioNTech Vaccine Response in Kids

The Pfizer-BioNTech SARS-CoV-2 vaccine in a lower-dose format appears to generate an immune response among children, according to the Washington Post.

Chicken Changes to Prevent Disease

The Guardian writes that researchers are looking at gene editing chickens to help prevent future pandemics.

PNAS Papers on Siberian Dog Ancestry, Insect Reproduction, Hippocampal Neurogenesis

In PNAS this week: ancestry and admixture among Siberian dogs, hormone role in fruit fly reproduction, and more.